12 results about "Cinnoline" patented technology

The invention belongs to the technical field of organic synthesis, and particularly relates to a method for photochemically synthesizing a benzo [c] cinnoline compound through an azo compound. The method for photochemically synthesizing the benzo [c] cinnoline compound through the azo compound comprises the following steps that an azobenzene compound, lewis acid and an oxidizing agent are added into an organic solvent and react under the condition of white light irradiation at the temperature of 40-50 DEG C, water quenching is conducted after the reaction is completed, then separation and purification are conducted, and the product benzo [c] cinnoline compound is obtained. The method has the advantages of simple operation, low toxicity of reactants, no need of addition of noble metals, easy separation of products and high yield.

The application discloses a cinnoline PAR4 antagonist and medical application thereof. The application relates to a compound of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts, esters, solvates or prodrugs thereof. The compound of the application can inhibit and prevent platelet aggregation induced by PAR4, can be used for treating and preventing thromboembolic diseases, and thus can be used as an anti-platelet drug.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido-pyrazine, quinoline, pyrazino-pyridazine, pyrimido-pyrimidine, quinazoline, quinoxaline or cinnoline ring system) which function as inhibitors of DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8 / 19, PI3K, PDGFrA / B, mTOR, WNT, homeodomain-interacting kinases (HIPKs), and / or CMGC kinases leading to inhibition of WNT signaling, and their use as therapeutics for the treatment of Alzheimer's disease, down syndrome, Parkinson's disease, Huntington's disease, diabetes, autoimmune diseases, inflammatory disorders (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer and metastatic colorectal cancer (e.g., metastatic colorectal cancer in the liver)), and other diseases.

Compounds of the Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling weeds, in particular in crops of useful plants.

The invention discloses a preparation method and application of a porous organic polymer adsorption material based on a nitrogen-containing heterocyclic skeleton. The material is prepared by taking benzo [c] cinnoline, pyridazine or phenanthroline derivatives as a nitrogen-containing skeleton, introducing vinyl through palladium-catalyzed coupling reaction and then polymerizing, has a micropore-mesopore hierarchical structure, and has the specific surface area of 214-893 m < 2 > / g. According to the material, efficient selective adsorption on SO2 is achieved through S delta < + >... N delta <-> dipole interaction, the SO2 adsorption capacity reaches 9.75 mmol / g under the conditions of 298 K and 1 bar, and the IAST selectivity of SO2 / CO2 (10: 90) reaches 450. A dynamic penetration experiment shows that the penetration time of the composite material to SO2 in SO2 / CO2 / N2 mixed gas reaches 969.34 min / g, and the capacity retention ratio after five times of circulation is greater than 95%. The method is simple in process, excellent in regeneration performance and suitable for efficient capture and separation of SO2 in industrial flue gas.

The present disclosure features compounds of the following Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same: wherein L is a linker; and B has the following structure:. Methods of treating BAF complex-associated disorders, such as cancer, are also disclosed.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido-pyrazine, quinoline, pyrazino-pyridazine, pyrimido-pyrimidine, quinazoline, quinoxaline or cinnoline ring system) which function as inhibitors of DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8 / 19, PI3K, PDGFrA / B, mTOR, WNT, homeodomain-interacting kinases (HIPKs), and / or CMGC kinases leading to inhibition of WNT signaling, and their use as therapeutics for the treatment of Alzheimer's disease, down syndrome, Parkinson's disease, Huntington's disease, diabetes, autoimmune diseases, inflammatory disorders (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer and metastatic colorectal cancer (e.g., metastatic colorectal cancer in the liver)), and other diseases.

Compounds of formula (I), wherein the substituents are as defined in claim 1. The present application further relates to herbicidal compositions comprising a compound of formula (I) and to the use of compounds of formula (I) for controlling weeds, in particular in crops of useful plants.

The invention relates to preparation, synthesis and anticancer activity test of cinnoline carbazole compounds. The synthesis yield is high (88-95%), and the product is single, easy to purify and suitable for industrial large-scale production. In-vitro activity tests show that the compounds have certain proliferation inhibition activity on HepG2 (hepatoma carcinoma cells), NCI-H1688 (lung cancer cells), HT29 (colon cancer cells) and 143B (osteosarcoma cells), and part of the compounds have strong to excellent proliferation inhibition activity on specific cells, so that the compounds are potential anti-tumor drugs and can be used for preparing drugs for treating tumors. The compound can be used for preparing high-efficiency and low-toxicity antitumor drugs. The structural general formula of the cinnoline carbazole compound is shown in the specification.

The present application relates to pyrimidopyridone and pteridinone compounds of formula I, processes for their preparation and compositions comprising them. More particularly, the present application relates to compounds of formula I having activity as inhibitors of GCN2 kinase and their use in the treatment of diseases, disorders or conditions treatable by inhibition of GCN2 kinase, such as cancer and neuronal diseases. (I).

Provided herein are methods for providing an anti-epileptic seizure effect in a subject by administering an effective amount of a compound of formula (I) (also referred to as BAER-101 or AZD7325), in particular (4-amino-8-(2-fluoro-6-methoxy-phenyl)-N-propyl-cinnolin-3-carboxamide). The compounds of formula (I) exhibit efficacy in preventing and reducing epileptic seizures when administered to a subject in need thereof. The method provides a promising method for controlling epileptic seizures and related conditions in a patient, thereby addressing the needs in the field of neurology and pharmaceuticals.

The triptyclocinnoline compound provided by the patent application further incorporates triptycene on the cinnoline group, enhances the electron transport property, and matches the electron-withdrawing group and weak electron-donating group for regulating the LUMO energy level and electron injection performance of the compound, so that the triptyclocinnoline compound has good electron mobility and electron transport property, and further can form good n-doping effect with the n-dopant, and improve the electron transport performance of the compound and the n-dopant composition. By using the above two advantages, the organic electroluminescent device prepared by using the triptyclocinnoline compound as the electron transport material will have the beneficial effects of low driving voltage, high luminous efficiency and long device life, solve the problems of insufficient electron transport property of the electron transport material and unbalanced carriers of the device, and achieve the effect of improving the device life.